IgA肾病作为我国最常见的原发性肾小球肾炎,其治疗方式已从既往的激素时代迈向靶向治疗时代,2021KDIGO指南更新的建议中国IgA患者使用羟氯喹,泰它西普、肠道靶向释放的布地奈德的问世为IgA肾病治疗提供新的方向,大大降低了长期激素治疗带来的副作用,提高了患者的生存质量。本文综述了IgA肾病的治疗手段,为IgA肾病治疗提供参考。
IgA nephropathy is the most common primary glomerulonephritis in China, and its treatment has moved from the previous era of hormones to the era of targeted therapy. The updated 2021KDIGO guidelines suggest the use of hydroxychloroquine for IgA patients in China, and the advent of Teli-tacicept and intestinal targeted release of budesonide provides a new direction for the treatment of IgA nephropathy. It greatly reduced the side effects of long-term hormone therapy and improved the quality of life of patients. This article reviews the treatment of IgA nephropathy and provides a reference for the treatment of IgA nephropathy.
IgA肾病,治疗进展, IgA Nephropathy Progress of Treatment摘要
IgA nephropathy is the most common primary glomerulonephritis in China, and its treatment has moved from the previous era of hormones to the era of targeted therapy. The updated 2021KDIGO guidelines suggest the use of hydroxychloroquine for IgA patients in China, and the advent of Telitacicept and intestinal targeted release of budesonide provides a new direction for the treatment of IgA nephropathy. It greatly reduced the side effects of long-term hormone therapy and improved the quality of life of patients. This article reviews the treatment of IgA nephropathy and provides a reference for the treatment of IgA nephropathy.
IgAN发病机制尚不清楚,故至今还没有针对IgAN的特效药物问世。控制血压达标,控盐、使用肾素–血管紧张素系统抑制剂(Renin angiotensin system inhibitors, RASi)是IgAN患者治疗的基石。近年来,IgAN发病机制研究有了一些新的进展,这为临床治疗提供了新的治疗方向。同时,临床研究也有了更多循证医学证据,本文就IgAN的治疗进展作综述如下。
张嘉欣,谢席胜. IgA肾病治疗新进展The New Progress of Treatment in IgA Nephropathy[J]. 临床医学进展, 2022, 12(08): 7032-7041. https://doi.org/10.12677/ACM.2022.1281012
参考文献ReferencesMedjeral-Thomas, N.R. and O’Shaughnessy, M.M. (2020) Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy. Advances in Chronic Kidney Disease, 27, 111-119. <br>https://doi.org/10.1053/j.ackd.2019.12.004Kiryluk, K., Li, Y., Sanna-Cherchi, S., et al. (2012) Ge-ographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLOS Genetics, 8, e1002765.
<br>https://doi.org/10.1371/journal.pgen.1002765Li, L.S. and Liu, Z.H. (2004) Epidemiologic Data of Renal Diseases from a Single Unit in China: Analysis Based on 13,519 Renal Biopsies. Kidney International, 66, 920-923. <br>https://doi.org/10.1111/j.1523-1755.2004.00837.xPattrapornpisut, P., Avila-Casado, C. and Reich, H.N. (2021) IgA Nephropathy: Core Curriculum 2021. American Journal of Kidney Diseases, 78, 429-441. <br>https://doi.org/10.1053/j.ajkd.2021.01.024Suzuki, K., Honda, K., Tanabe, K., et al. (2003) Incidence of La-tent Mesangial IgA Deposition in Renal Allograft Donors in Japan. Kidney International, 63, 2286-2294. <br>https://doi.org/10.1046/j.1523-1755.63.6s.2.xRajasekaran, A., Julian, B.A. and Rizk, D.V. (2021) IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences, 361, 176-194. <br>https://doi.org/10.1016/j.amjms.2020.10.003Magistroni, R., D’agati, V.D., Appel, G.B., et al. (2015) New Developments in the Genetics, Pathogenesis, and Therapy of IgA Nephropathy. Kidney International, 88, 974-989. <br>https://doi.org/10.1038/ki.2015.252He, B., Xu, W., Santini, P.A., et al. (2007) Intestinal Bacteria Trigger T Cell-Independent Immunoglobulin A2 Class Switching by Inducing Epithelial-Cell Secretion of the Cytokine APRIL. Immunity, 26, 812-826.
<br>https://doi.org/10.1016/j.immuni.2007.04.014Lehrer, R.I. and Lu, W. (2012) α-Defensins in Human Innate Immunity. Immunological Reviews, 245, 84-112.
<br>https://doi.org/10.1111/j.1600-065X.2011.01082.xSanchez-Rodriguez, E., Southard, C.T. and Kiryluk, K. (2021) GWAS-Based Discoveries in IgA Nephropathy, Membranous Nephropathy, and Steroid-Sensitive Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 16, 458-466. <br>https://doi.org/10.2215/CJN.14031119Hiki, Y., Odani, H., Takahashi, M., et al. (2001) Mass Spectrometry Proves Under-O-Glycosylation of Glomerular IgA1 in IgA Nephropathy. Kidney International, 59, 1077-1085.
<br>https://doi.org/10.1046/j.1523-1755.2001.0590031077.xAllen, A.C., Bailey, E.M. and Brenchley, P.E. (2001) Mesangial IgA1 in IgA Nephropathy Exhibits Aberrant O-Glycosylation: Observations in Three Patients. Kidney Inter-national, 60, 969-973.
<br>https://doi.org/10.1046/j.1523-1755.2001.060003969.xHe, J.W., Zhou, X.J., Lv, J.C., et al. (2020) Perspec-tives on How Mucosal Immune Responses, Infections and Gut Microbiome Shape IgA Nephropathy and Future Thera-pies. Theranostics, 10, 11462-11478.
<br>https://doi.org/10.7150/thno.49778Aguilera, M., Cerda-Cuellar, M. and Martinez, V. (2015) Antibi-otic-Induced Dysbiosis Alters Host-Bacterial Interactions and Leads to Colonic Sensory and Motor Changes in Mice. Gut Microbes, 6, 10-23.
<br>https://doi.org/10.4161/19490976.2014.990790Yang, C., Mogno, I., Contijoch, E.J., et al. (2020) Fecal IgA Levels Are Determined by Strain-Level Differences in Bacteroides ovatus and Are Modifiable by Gut Microbiota Ma-nipulation. Cell Host & Microbe, 27, 467-475.E6.
<br>https://doi.org/10.1016/j.chom.2020.01.016Kidney Disease: Improving Global Outcomes Glomerular Dis-eases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276.Robert, T., Cambier, A. and Hertig, A. (2016) Intensive Supportive Care Plus Immu-nosuppression in IgA Nephropathy. New England Journal of Medicine, 374, 991-993. <br>https://doi.org/10.1056/NEJMc1600141Le, W., Liang, S., Hu, Y., et al. (2012) Long-Term Renal Survival and Related Risk Factors in Patients with IgA Nephropathy: Results from a Cohort of 1155 Cases in a Chinese Adult Population. Nephrology, Dialysis, Transplantation, 27, 1479-1485. <br>https://doi.org/10.1093/ndt/gfr527Geng, D.F., Sun, W.F., Yang, L., et al. (2014) Antiproteinuric Effect of Angiotensin Receptor Blockers in Normotensive Pa-tients with Proteinuria: A Meta-Analysis of Randomized Controlled Trials. Journal of the Renin-Angiotensin- Aldoste-rone System, 15, 44-51. <br>https://doi.org/10.1177/1470320312474054Makani, H., Bangalore, S., Desouza, K.A., et al. (2013) Efficacy and Safety of Dual Blockade of the Renin-Angiotensin System: Meta-Analysis of Random-ised Trials. British Medical Journal, 346, f360.
<br>https://doi.org/10.1136/bmj.f360Lennartz, D.P., Seikrit, C., Wied, S., et al. (2020) Single versus Dual Blockade of the Renin-Angiotensin System in Patients with IgA Nephropathy. Journal of Nephrology, 33, 1231-1239. <br>https://doi.org/10.1007/s40620-020-00836-8Huo, Z., Ye, H., Ye, P., et al. (2021) Comparative Efficacy of Different Renin Angiotensin System Blockade Therapies in Patients with IgA Nephropathy: A Bayesian Network Me-ta-Analysis of 17 RCTs. PeerJ, 9, e11661.
<br>https://doi.org/10.7717/peerj.11661Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group (2012) KDIGO 2012 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Interna-tional, 2, S1-143.Floege, J. (2019) Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentar-ium Just Increase? American Journal of Kidney Diseases, 74, 6-8. <br>https://doi.org/10.1053/j.ajkd.2019.02.022Rauen, T. and Floege, J. (2017) Inflammation in IgA Nephropathy. Pediatric Nephrology, 32, 2215-2224.
<br>https://doi.org/10.1007/s00467-017-3628-1Lv, J., Zhang, H., Chen, Y., et al. (2009) Combination Therapy of Prednisone and ACE Inhibitor versus ACE-Inhibitor Therapy Alone in Patients with IgA Nephropathy: A Random-ized Controlled Trial. American Journal of Kidney Diseases, 53, 26-32. <br>https://doi.org/10.1053/j.ajkd.2008.07.029Rauen, T., Wied, S., Fitzner, C., et al. (2020) After Ten Years of Follow-Up, No Difference between Supportive Care Plus Immunosuppression and Supportive Care Alone in IgA Nephropathy. Kidney International, 98, 1044-1052.
<br>https://doi.org/10.1016/j.kint.2020.04.046Lv, J., Zhang, H., Wong, M.G., et al. (2017) Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial. Journal of the American Medical Association, 318, 432-442.
<br>https://doi.org/10.1001/jama.2017.9362Wong, M.G., Lv, J., Hladunewich, M.A., et al. (2021) The Thera-peutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 52, 827-836.
<br>https://doi.org/10.1159/000519812刘开翔, 龚蓉, 谢席胜. 单纯糖皮质激素治疗IgA肾病的系统评价[J]. 中国中西医结合肾病杂志, 2020, 21(4): 321-327.Nagasawa, Y., Yamamoto, R., Shinzawa, M., et al. (2020) Ef-ficacy of Corticosteroid Therapy for IgA Nephropathy Patients Stratified by Kidney Function and Proteinuria. Clinical and Experimental Nephrology, 24, 927-934.
<br>https://doi.org/10.1007/s10157-020-01918-4Natale, P., Palmer, S.C., Ruospo, M., et al. (2020) Immunosup-pressive Agents for Treating IgA Nephropathy. Cochrane Database of Systematic Reviews, 3, CD003965. <br>https://doi.org/10.1002/14651858.CD003965.pub3Fellström, B.C., Barratt, J. and Cook, H. (2017) Target-ed-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet, 389, 2117-2127.
<br>https://doi.org/10.1016/S0140-6736(17)30550-0Sweden, S. (2020) Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial. EU Market Abuse Regulation.Liu, L.J., Yang, Y.Z., Shi, S.F., et al. (2019) Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 74, 15-22.
<br>https://doi.org/10.1053/j.ajkd.2019.01.026Yang, Y.Z., Liu, L.J., Shi, S.F., et al. (2018) Effects of Hy-droxychloroquine on Proteinuria in Immunoglobulin A Nephropathy. American Journal of Nephrology, 47, 145-152. <br>https://doi.org/10.1159/000487330Yang, Y.Z., Chen, P., Liu, L.J., et al. (2019) Comparison of the Effects of Hydroxychloroquine and Corticosteroid Treatment on Proteinuria in IgA Nephropathy: A Case-Control Study. BMC Nephrology, 20, Article No. 297.
<br>https://doi.org/10.1186/s12882-019-1488-6Tang, C., Lv, J.C., Shi, S.F., et al. (2020) Effect of Hy-droxychloroquine in Patients with IgA Nephropathy with Insufficient Responses to Immunosuppressive Therapy: A Retrospective Case-Control Study. BMC Nephrology, 21, Article No. 469. <br>https://doi.org/10.1186/s12882-020-02141-9Yu, Y., Peng, J. and Zhou, L. (2020) Short-Term and Long-Term Efficacy, Safety Assessment and Independent Prognostic Risk Factors of Hydroxychloroquine in the Treat-ment of IgA Nephropathy. Acta Medica Mediterranea, 36, 1345-1350.Tang, C., Lv, J.C., Shi, S.F., et al. (2021) Long-Term Safety and Efficacy of Hydroxychloroquine in Patients with IgA Nephropathy: A Single-Center Experience. Journal of Nephrology, 35, 429-440.
<br>https://doi.org/10.1007/s40620-021-00988-1Tang, C., Si, F.L., Yao, Y.X., et al. (2022) The Efficacy and Safety of Hydroxychloroquine in Pregnant Patients with IgA Nephropathy: A Retrospective Cohort Study. Nephrology, 27, 155-161. <br>https://doi.org/10.1111/nep.13991陈香美, 陈仆, 汤力. 吗替麦考酚酯治疗重症IgA肾病的随机对照试验[J]. 中华医学杂志, 2002, 82(12): 796-801.Tang, S., Leung, J.C.K. and Chan, L.Y.Y. (2005) Mycophenolate Mofetil Alleviates Persistent Proteinuria in IgA Nephropathy. Kidney International, 68, 802-812. <br>https://doi.org/10.1111/j.1523-1755.2005.00460.xHou, J.H., Le, W.B., Chen, N., et al. (2017) Mycopheno-late Mofetil Combined With Prednisone versus Full-Dose Prednisone in IgA Nephropathy with Active Proliferative Le-sions: A Randomized Controlled Trial. American Journal of Kidney Diseases, 69, 788-795. <br>https://doi.org/10.1053/j.ajkd.2016.11.027Zhao, J., Ma, F., Bai, M., et al. (2021) Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy with Stage 3 or 4 CKD: A Retrospective Cohort Study. Clinical Therapeutics, 43, 859-870.
<br>https://doi.org/10.1016/j.clinthera.2021.03.009Maes, B.D., Oyen, R. and Claes, K. (2004) Mycophenolate Mofetil in IgA Nephropathy: Results of a 3-Year Prospective Placebo-Controlled Randomized Study. Kidney Interna-tional, 65, 1842-1849.
<br>https://doi.org/10.1111/j.1523-1755.2004.00588.xFrisch, G., Lin, J., Rosenstock, J., et al. (2005) Mycophe-nolate Mofetil (MMF) vs Placebo in Patients with Moderately Advanced IgA Nephropathy: A Double-Blind Random-ized Controlled Trial. Nephrology, Dialysis, Transplantation, 20, 2139-2145. <br>https://doi.org/10.1093/ndt/gfh974Lafayette, R.A., Canetta, P.A., Rovin, B.H., et al. (2017) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American So-ciety of Nephrology: JASN, 28, 1306-1313.
<br>https://doi.org/10.1681/ASN.2016060640Fenogli, R., Sciascia, S. and Naretto, C. (2020) Rituximab in Se-vere Immunoglobulin-A Vasculitis (Henoch-Schönlein) with Aggressive Nephritis. Clinical and Experimental Rheuma-tology, 38, 195-200.Tan, S.L., Potezny, T. and Li, J.Y. (2021) The Successful Use of Rituximab in Crescentic IgA Nephropathy with Concurrent ANCA Positivity. Nephrology, 27, 216-217. <br>https://doi.org/10.1111/nep.13950Chancharoenthana, W., Townamchai, N., Leelahavanichkul, A., et al. (2017) Rituximab for Recurrent IgA Nephropathy in Kidney Transplantation: A Report of Three Cases and Proposed Mechanisms. Nephrology, 22, 65-71.
<br>https://doi.org/10.1111/nep.12722Dhillon, S. (2021) Telitacicept: First Approval. Drugs, 81, 1671-1675. <br>https://doi.org/10.1007/s40265-021-01591-1Samy, E., Wax, S., Huard, B., et al. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Immunol-ogy, 36, 3-19.
<br>https://doi.org/10.1080/08830185.2016.1276903Parodis, I., Stockfelt, M. and Sjowall, C. (2020) B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Frontiers in Medicine, 7, Article No. 316. <br>https://doi.org/10.3389/fmed.2020.00316Lv, J., Liu, L. and Hao, C.M. (2021) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Telitacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Pro-ceedings of the ASN Kidney Week 2021, San Diego, 4-7 November 2021.Mosenzon, O., Wiviott, S.D., Cahn, A., et al. (2019) Effects of Dapagliflozin on Development and Progression of Kidney Disease in Patients with Type 2 Diabe-tes: An Analysis from the DECLARE-TIMI 58 Randomised Trial. The Lancet Diabetes & Endocrinology, 7, 606-617. <br>https://doi.org/10.1016/S2213-8587(19)30180-9Heerspink, H.J.L., Stefansson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383, 1436-1446. <br>https://doi.org/10.1056/NEJMoa2024816Cherney, D.Z.I., Dekkers, C.C.J., Barbour, S.J., et al. (2020) Ef-fects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial. The Lancet Diabetes & Endocrinology, 8, 582-593. <br>https://doi.org/10.1016/S2213-8587(20)30162-5